Skip to content

Technology-based Analysis of Movement Disorders

Technology-based Analysis of Movement Disorders

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04591132
Enrollment
50
Registered
2020-10-19
Start date
2020-11-01
Completion date
2023-10-01
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Movement Disorders

Brief summary

Objectives: To generate pilot data to investigate the feasibility and the potential use in clinical practice of technology based objective measures of motor performances in patients affected by different movement disorders. To correlate kinematics findings with demographic and clinical details. Trial design and methods: Participants enrolled in prof. Bhatia's movement disorders clinic, will be classifies according to the main movement disorder, specifically, tremor, parkinsonism, dystonia, chorea, ataxia. In the study visit (one day only), they will undergo a clinical evaluation using the appropriate clinical scales (respectively, Fahn-Tolosa-Marin tremor rating scale, MDS-UPDRS Part III, Toronto Western Spasmodic Torticollis Rating Scale 2, Unified Hungtington Disease Rating scale and Scale for the Assessment and Rating of Ataxia) and a kinematic evaluation, using wearables and an infra-red and LED markers system. Then the protocol is concluded and they will continue the routine clinical follow-up

Interventions

motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors

Sponsors

University College, London
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of parkinsonism and/or dystonia and/or tremor due to: 1. idiopatic parkinson's disease 2. atypical parkinsonism 3. sporadic or inherited/genetic dystonia 4. young-onset Parkinson's disease 5. Ataxia syndrome 6. Choereic syndrome 7. Essential tremor 8. Dystonic tremor * 18 to 80 years of age * Willing and able to provide informed consent * able to walk unassisted

Exclusion criteria

* Change in pharmacological therapy in the last 3 months. * Participated in a clinical drug trial up to 3 months before inclusion into the present study * Orthopaedical comorbidities affecting gait or posture. * Cognitive deficit

Design outcomes

Primary

MeasureTime frameDescription
gait metricsup to 6 weeks after enrolmentgait cycles measures (step length, phase duration, number of steps) practice of technology based objective measures of motor performances in patients affected by different movement disorders, to objectively evaluate the disease burden, the efficacy of therapeutic interventions and having a deeper phenotyping of motor disabilities.
tremor peak frequenceup to 6 weeks after enrolmentfourier analysis for peak frequence of tremor
neck ROMup to 6 weeks after enrolmentrange of motion of the neck in x,y and z axis
bradykinesia evaluationup to 6 weeks after enrolmentamplitude of repeated limb movements over time

Secondary

MeasureTime frameDescription
correlation with UPDRS gait Itemup to 6 weeks after enrolmentcorrelation of gait metrics with UPDRS gait score included.

Contacts

Primary Contactkailash P Bhatia
k.bhatia@ucl.ac.uk020 3448 4229
Backup Contactgiulia di lazzaro
giulia.dilazzaro@nhs.net02034484229

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026